Consequently, in addition to the three core AD CSF biomarkers (Aβ, T-tau, P-tau), many other molecules have been proposed or investigated as candidate biomarkers for differentiating AD from healthy controls or other causes of dementia, for monitoring disease progression or target engagement of novel candidate drugs, or for predicting the rate of cognitive decline [174]. Here, MAPT is linked to Mental deterioration.